TransMedics Group, Inc. (TMDX)
After hours:
| Previous Close | 132.65 |
| Open | 132.45 |
| Bid | 127.08 x 200 |
| Ask | 127.36 x 400 |
| Day's Range | 125.86 - 132.96 |
| 52 Week Range | 36.42 - 132.96 |
| Volume | |
| Avg. Volume | 905,560 |
| Market Cap | 4.192B |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
TransMedics Reports First Quarter 2024 Financial Results
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024.
- PR Newswire
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
- PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The gr
